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Background: Pulmonary artery hypertension (PAH) is characterized by vascular remodeling, high pulmonary
blood pressure, and right ventricular hypertrophy. Oxidative stress, inﬂammation and pulmonary artery remod-
eling are important components in PAH. Ellagic acid (EA) is a phenolic compound with anti-oxidative, anti-
inﬂammatory, and anti-proliferative properties. This study aimed to investigate whether EA could prevent the
development of monocrotaline (MCT)-induced PAH in rats.
Methods:Male Sprague-Dawley rats received EA (30 and 50mg/kg/day) or vehicle one day after a single-dose of
monocrotaline (MCT, 60mg/kg). Hemodynamic changes, right ventricular hypertrophy, and lungmorphological
features were assessed 4 weeks later. Activation of the NLRP3 (NACHT, LRR, and PYD domain-containing protein
3) inﬂammasome pathway in the lungs was assessed using Western blot analysis.
Results:MCT induced PAH, oxidative stress, and NLRP3 inﬂammasome activation in vehicle-treated rats. EA re-
duced the right ventricle systolic pressure, the right ventricular hypertrophy and the wall thickness/external di-
ameter ratio of the pulmonary arteries compared with vehicle. EA also inhibited the MCT-induced elevation of
oxidative stress, NLRP3, and caspase-1, IL-β in the lungs and the elevated levels of brain natriuretic peptide
(BNP) and inﬂammatory cytokines in serum.
Conclusions: Ellagic acid amelioratesmonocrotaline-induced pulmonary artery hypertension via exerting its anti-
oxidative property inhibiting NLRP3 inﬂammasome signal pathway in rats.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
The understanding of pulmonary artery hypertension (PAH) has un-
dergone a paradigm shift in recent years. PAH was once thought to be
caused by increased vasoconstrictor tone; however, vasodilators did not
have the expected satisfactory clinical outcome. The characteristic vascu-
lar abnormalities of PAH include abnormal muscularization of distal
precapillary arteries and medial thickening of large pulmonary muscular
arteries [1]. PAH is now seen as a vasculopathy inwhich structural chang-
es driven by excessive vascular cell growth and inﬂammation, alongwith
the recruitment and inﬁltration of circulating cells, play a major role.
The pro-inﬂammatory cytokine interleukin 1-beta (IL-1β) has been
implicated in PAH [2–7]. The NLRP3 inﬂammasome, comprising the
NLR protein NLRP3, the adapter ASC, and pro-caspase-1, is central to
the activation of IL-1β [8,9] and plays a key role in innate immunity
[9] and lung injury [10,11].rdiac Surgery, the First Afﬁliated
Guangzhou 510080, China.
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eliability and freedom frombias
land Ltd. This is an open access articleThe generation of reactive oxygen species (ROS) is the central ele-
ment regulating NLRP3 activation [8,12]. Coincidentally, multiple stud-
ies implicate oxidative stress (OS) in the development of PAH [13–16].
OS has been associated with alterations in the ROS and nitric oxide sig-
naling pathways. Dysregulation of the oxidant/antioxidant balance im-
pairs vascular tone and contributes to the pathological activation of
antiapoptotic and mitogenic pathways, leading to cell proliferation
and obliteration of the vasculature [17]. Antioxidant intervention
shows protective effects in experimental PAH [14,15]. However, the un-
derlyingmechanismhas never been fully understood. As a polyphenolic
compound, ellagic acid (EA) possessesmultiple biological activities such
as radical scavenging [18], antioxidant [19,20] and anti-proliferative ac-
tivities [21]. The aim of the present study was to advance the under-
standing of the detailed interaction between antioxidants, OS, the
NLRP3 inﬂammasome, IL-1β and PAH.
Considering the critical role of the NLRP3 inﬂammasome in innate
immunity and the multiple biological activities of EA, we hypothesized
that the NLRP3 inﬂammasome pathway may be activated in PAH and
that EA may prevent the progression of PAH. To test our hypothesis,
we investigated the chronic efﬁcacy of EA treatment in monocrotaline
(MCT)-treated rats. We particularly addressed the question of whether
EA can exert beneﬁcial effects on PAH through inhibition of the NLRP3
inﬂammasome.under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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2.1. Animal model
Male Sprague-Dawley rats (200–220 g) were provided by the Sun Yat-sen University
Laboratory Animal Center (Guangzhou, China). The animals receivedhumane care in com-
pliance with the ‘Principles of Laboratory Animal Care’ formulated by the National Society
for Medical Research and the ‘Guide for the Care and Use of Laboratory Animals’ prepared
by the Institute of Laboratory Animal Resources andpublished by theNational Institutes of
Health (NIH Publication No. 86-23, revised 1996).
Rats were randomly divided into four groups as follows: (1) Control group (n=8) re-
ceived normal saline (NS) + vehicle, (2) MCT group (n = 10) received MCT + vehicle,
(3) EA + MCT group (n = 8) received MCT + EA at 30 mg/kg/day and (4) EA-high
group (n = 8) received MCT + EA at 50 mg/kg/day. The PAH model was established by
a single dose of 60 mg/kg of MCT injected intraperitoneally, while the Control group
was injected with NS only. MCT (Sigma-Aldrich, St. Louis, MO, US) was dissolved in 1 N
HCl neutralized with 1 N NaOH and diluted with NS. EA (Sigma-Aldrich, St. Louis, MO,
US) dissolves poorly under natural aqueous environments. Methyl-beta-cyclodextrin
(Me-β-CD) was applied to increase bioavailability of EA [22]. MCT-treated rats received,
by gavage, either EA (30 and 50 mg/kg body weight, in 10% Me-β-CD). 10% Me-β-CD
was used as vehicle. The EA treatments started one day after the MCT injection and
were maintained daily for 4 weeks. Body weight was measured weekly to adjust the
dose accordingly.
2.2. Hemodynamic measurements
Rats were anesthetized with pentobarbital (60 mg/kg, i.p). Right ventricle systolic
pressure (RVSP) was measured by right heart puncture [14]. Systemic arterial pressureFig. 1. EA alleviates hemodynamic changes and right ventricular hypertrophy in MCT-induced
dependent manner presented, the RVSP of EA-high group was lower than EA-MCT group (p b 0
namic data (RVSP) fromBIOPACMP100 data acquisition systemwere showed in Fig. 1C. Data re
versus Control group. n= 8 per group. MCT, monocrotaline; PAH, pulmonary artery hypertens
tricular weight to left ventricular plus septal weight ratio.wasmonitored by cannulating the right carotid artery. Heart rate was monitored by elec-
trocardiography. The RVSP was measured using 22-gauge I.V. catheter that was inserted
into the right ventricle without regular thoracotomy, reducing blood loss and hemody-
namic changes. Brieﬂy, tracheotomywas performed, and rats were mechanically ventilat-
ed with room air (Harvard Rodent Ventilator, model 683; Harvard Apparatus Co., Millis,
MA) using a tidal volume of 8 ml/kg and a respiratory rate of 80 breaths per min. After
the thoracic cavity was opened using an upper abdominal incision approach by freeing
the xiphoid process and opening the diaphragm, a 22-gauge I.V. catheter (Insyte-W,
Becton Dickinson, Utah, U.S.) was inserted directly into the right ventricle. Systemic arte-
rial pressure and RVSP were recorded using a miniature pressure transducer (TSD104A,
BIOPAC Systems Inc., U.S.) digitized by a BIOPAC MP100 data acquisition system. After
hemodynamic analysis, blood from the RV were stored at room temperature for 1 h and
then centrifuged at 3000 rpm at 4 °C for 15 min. Blood serum was collected and stored
at−80 °C, and the ratswere euthanized byexsanguination. Lungs andheartswere excised
for Western blotting (stored at−80 °C) and histological analysis.2.3. Right ventricular hypertrophy and morphological measurements
The RV wall was separated from the LV wall and the ventricular septum and then
weighed. The weight ratio of the right ventricle to the left ventricle plus the septum
(RV/(LV + S) ratio) was calculated as an index of right ventricular hypertrophy. Lung tis-
sue was ﬂushed with cold saline through the pulmonary artery. The lung tissues were
ﬁxed in 4% paraformaldehyde, embedded in parafﬁn, and sectioned. After hematoxylin
and eosin (HE) stainingwas performed, these sectionswere examined using light micros-
copy (Inverted FluorescenceMicroscope, NIKON Eclipse Ti-E, NIKON, Japan). Morphomet-
ric analysis was performed in the pulmonary artery with an external diameter of 25–
100 μm. Medial wall thickness was calculated with the following formula: medialPAH 4 weeks after MCT exposure. EA decreased RVSP in MCT-treated rats. Further a dose-
.05). EA also reduced the RV/(LV + S) ratio in MCT-treated rats. Representative hemody-
presentmeans±SD. *p b 0.05 versus Control group;▲p b 0.05 versusMCT group; #p b 0.05
ion; EA, ellagic acid; RVSP, right ventricle systolic pressure; RV/LV+ S ratio, the right ven-
Fig. 2. EA prevents pulmonary vascular remodeling inMCT-treated rats. A through D, Representative hematoxylin and eosin (HE) staining images compare the arteriole wall thickness in
rats. Original magniﬁcation ×400, scale bars = 50 μm. The pulmonary arteriole walls in the Control group were thin and single layered. The intima, media and extima were difﬁcult to
distinguish. Conspicuous pulmonary vascular remodeling could be observed inMCT group, characterized by pulmonary arteriolemedia muscularization and intima and extima thickness.
After EA treatment, medial hypertrophy decreased. E, Quantiﬁcation analysis of percentmedial thickness for arteriole (25–100 μm in external diameter) showed that EA reduced theme-
dial wall thickness inMCT-treated rats compared with Controls. Data represent means± SD. *p b 0.05 versus Control group; ▲p b 0.05 versusMCT group; #p b 0.05 versus Control group.
n = 8 per group. EA, ellagic acid; MCT, monocrotaline.
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20 randomly selected vessels from each rat were counted, and the averagewas calculated.
2.4. Enzyme-linked immunosorbent assay for BNP in serum
BNP is a 32 amino acid polypeptide secreted by myocytes in response to excessive
stretching of ventricles. It is used for the diagnosis and staging of heart failure [23]. Of
the range of biomarkers investigated in PAH to date, only BNP and its N-terminal cleavage
product have been included as prognostic parameters in PAH treatment guidelines [24,
25]. Their levels elevate in proportion to the degree of RV dysfunction and RV remodeling
in PAH. Blood samples from the RVwere stored at room temperature for 1 h and then cen-
trifuged at 3000 rpm at 4 °C for 15min. Serum samples were collected and stored at−80
°C. BNP levels were analyzed using a commercial EIA kit (RayBiotech, Norcross, GA, USA)
according to the manufacturer's instructions.
2.5. Measurement of oxidative stress in lung
Lung tissues were homogenized in saline at 4 °C. The homogenates were centrifuged at
3000 rpm at 4 °C for 10min. The protein concentrations of the supernatants weremeasuredwith the BCA Protein Assay kit (Beyotime Institute of Biotechnology, Jiangsu, China). In lung
homogenate supernatants, superoxide dismutase (SOD) activity was determined using SOD
assay kits (Jiancheng Bio-Technology, Nanjing, China) and is expressed as U/mg protein. Fur-
thermore, the lipid peroxide product malondialdehyde (MDA) as an index of lipid peroxida-
tion and a stable indicator of OS, was determined with the TBA assay using an MDA kit
(Jiancheng Bio-Technology, Nanjing, China) and expressed as nmol/mg protein.
2.6. The Bio-Plex Pro™ rat cytokine immunoassay
We determined the levels of IL-1β, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor alpha
(TNF-α), interferon gamma (IFN-γ) and macrophage inﬂammatory protein 1 alpha
(MIP-1α) in serum using the commercially available BPLX Pro Reagent Kit (Bio-Rad, Her-
cules, CA, USA). The Bio-Plex Pro™ rat cytokine immunoassaywas performed according to
the manufacturer's instructions.
2.7. Western blotting
Lung tissues were homogenized in ice-cold lysis buffer (Cell Signaling Technologies,
Beverly, MA) and then centrifuged at 10,000 × g for 20 min. The protein concentrations
Fig. 3. EA decreases serum BNP levels inMCT-induced PAH rats. Enzyme-linked immuno-
sorbent assay showed that MCT-treated rats had higher BNP levels compared with Con-
trols, whereas EA supplementation reduced the MCT-induced increase in BNP levels.
Data represent means ± SD. n.s., not signiﬁcant; *p b 0.05 versus Control group;
▲p b 0.05 versus MCT group. n = 8 per group. EA, ellagic acid; MCT, monocrotaline;
PAH, pulmonary artery hypertension; BNP, B-type natriuretic peptide.
Fig. 4. EA suppresses OS in the lungs ofMCT-treated rats. Data representmeans± SD. SOD
activity in theMCT group was lower than that in the Control group, but in the EA group, it
was higher than in the MCT group. The MDA level in the lungs of the MCT group was
higher than that in the Control group, and in the EA group, it was lower than in the MCT
group. n.s., not signiﬁcant; *p b 0.05 versus Control group; ▲p b 0.05 versus MCT group.
n = 8 rats per group. EA, ellagic acid; MCT, monocrotaline; SOD, superoxide dismutase;
MDA, malondialdehyde.
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Biotechnology, Jiangsu, China). The total proteins were incubated in boiling water for
10min. Equal amounts of total protein were separated on 8–12% SDS-PAGE gels and elec-
trophoretically transferred to polyvinylidene diﬂuoride (PVDF) membranes (Millipore,
Billerica, MA, U.S.) pre-activated by methanol in the transfer buffer. The membranes
were blocked with 5% skimmedmilk for 1 h and incubated with speciﬁc primary antibod-
ies in 3% BSA at 4 °C with gentle shaking, overnight. β-actin (Cell Signaling Technologies,
Beverly, MA) was used as a loading control. Immunoreactive bands were detected using
HRP-conjugated goat anti-rabbit IgG as the secondary antibody (1:2000) (Cell Signaling
Technologies, Beverly, MA). Then, protein bands were detected by enhanced chemilumi-
nescence (Millipore, Bedford, MA). Primary antibodies included rabbit anti-rat polyclonal
antibodies against caspase-1 (1:500) (Abcam Ltd. Hong Kong), NLRP3 (1:500) (LifeSpan
BioSciences, Seattle, WA), IL-1β (1:1000) (Abcam Ltd. Hong Kong) and rat β-actin
(1:1,000) (Cell Signaling Technologies, Beverly, MA).
2.8. Statistical analysis
All above assessments were carried out in a blinded fashion. All data were expressed
as the mean ± standard deviation (SD). Differences in measured variables between
groups were determined by one-way analysis of variance followed by the Student–New-
man–Keul test for multiple comparisons. p-Values b 0.05 were considered statistically
signiﬁcant. All statistical analyses were performed using SPSS software (version 16.0).
3. Results
3.1. EA prevents the MCT-induced increase in RVSP, right ventricular
hypertrophy, and pulmonary artery remodeling
Only two rats in MCT group died during the course of this study. Nei-
ther MCT nor EA affected systemic artery pressure. MCT injection led to
lower body weight than Control rats (328.7 ± 19.6 g vs. 363.7 ± 19.2 g,
p b 0.05). EA administration didn't improve the decreasedweight growth
caused by MCT (p N 0.05). MCT-exposed rats developed right ventricular
hypertrophy (RV/(LV + S) ratio: 49.3 ± 7.4% vs. 27.8 + 1.5%, p b 0.05)
and PAH (RVSP: 69.5 ± 5.7 mm Hg vs. 36.5 ± 4.2 mm Hg, p b 0.05)
four weeks after MCT injection. EA treatment reduced the RVSP with
a dose-dependent manner. EA-high (50 mg/kg/day) group showed
lower RVSP than EA + MCT (30 mg/kg/day) group (47.8 ± 2.8 mm Hg
vs. 56.4 ± 3.7 mm Hg, p b 0.05), but still higher than Control group
(47.8 ± 2.8 mm Hg vs. 36.5 ± 4.2 mm Hg, p b 0.05) (Fig. 1A). EA +
MCT group got lower RV/(LV + S) ratio than MCT group (37.1 ± 2.2%
vs. 49.3 ± 7.4%, p b 0.05). However, EA-high group didn't show further
improvement of RV hypertrophy than EA + MCT group (p N 0.05)
(Fig. 1B).
MCT-exposed rats showed pulmonary artery remodeling (Fig. 2B).
Compared with controls, MCT-exposed rats demonstrated an increasedmedial thickness of pulmonary arteries (20.9 ± 3.7% vs. 11.3 ± 2.9%,
p b 0.05) (Fig. 2E). These lung pathological changes were ameliorated
by EA treatment (EA + MCT vs. MCT: 15.9 ± 2.8% vs. 20.9 ± 3.7%,
p b 0.05; EA-high vs. MCT: 14.9 ± 2.9% vs. 20.9 ± 3.7%, p b 0.05).
However, there was no dose-dependent manner found (Fig. 2E).
3.2. EA suppresses the MCT-induced increase in serum BNP
Plasma BNP is used for the diagnosis and staging of heart failure [23].
Four weeks after MCT administration, serum BNP levels were markedly
higher in MCT-injected rats than in Controls (876.3 ± 194.9 pg/ml vs.
278.3 ± 41.5 pg/ml, p b 0.05). This increase was suppressed by EA
(30 mg/kg/day) (418.1 pg/ml ± 142.2 pg/ml, p b 0.05) (Fig. 3).
3.3. EA attenuates OS in the lungs
The attenuation of OS by EA (30mg/kg/day)was associatedwith the
preservation of SOD activity as well as the down-regulation of MDA
(Fig. 4). Increasing evidence indicates that OS plays a causal role in the
development of PAH [13]. SOD activity was inhibited by MCT (3.9 ±
1.8 U/mg protein vs. 10.4 ± 1.3 U/mg protein, p b 0.05), whereas EA
treatment reversed this inhibition (8.6 ± 2.4 U/mg protein vs. 3.9 ±
Fig. 5. EA reduces inﬂammatory cytokine levels of serum inMCT-induced PAH rats. Select-
ed cytokines with divergent expression in the MCT group compared with the EA-treated
group. Expression levels in normal lungs are shown for comparison. Cytokines induced
during the progression of MCT-induced PAH that were suppressed by EA treatment in-
clude the inﬂammatory cytokines IL-1β, IL-2, IL-4, IL-6, IL-10, IFN-γ and MIP-1α. Analysis
was performed by the Bio-Plex Pro™ rat cytokine immunoassay. Data represent means±
SD. n.s., not signiﬁcant; *p b 0.05 versus Control group; ▲p b 0.05 versus MCT group;
#p b 0.05 versus Control group. n = 8 per group. EA, ellagic acid; MCT, monocrotaline;
PAH, pulmonary artery hypertension; IL-1β, interleukin-1beta; TNF-α, tumor necrosis fac-
tor alpha; IFN-γ, interferon gamma; MIP-1α, macrophage inﬂammatory protein 1 alpha.
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MCT induced an elevation of lungMDA levels (12.1±1.2 nmol/mgpro-
tein vs. 9.0 ± 1.6 nmol/mg protein, p b 0.05), while EA inhibited this
elevation (10 ± 1.4 nmol/mg protein vs. 12.1 ± 1.2 nmol/mg protein,
p b 0.05).
3.4. EA attenuates inﬂammatory cytokine levels in serum
Development of pulmonary artery hypertension was associated
with the up-regulation of inﬂammatory cytokines IL-1β (601.3 ± 277.9
pg/mg vs. 33.9 ± 21.5 pg/mg, p b 0.05), IL-2 (801.8 ± 234.1 pg/mg vs.
99.3 ± 44.2 pg/ml, p b 0.05), IL-4 (339.1 ± 127.5 pg/mg vs. 15.8 ± 5.5
pg/ml, p b 0.05), IL-6 (1000.1 ± 565.2 pg/mg vs. 20.3 ± 6.6 pg/ml, p b0.05), IL-10 (1810.9 ± 717.8 pg/mg vs. 514.1 ± 31.7 pg/ml, p b 0.05),
MIP-1α (186.3 ± 58.2 pg/mg vs. 30.5 ± 18.1 pg/ml, p b 0.05) and
IFN-γ (226.5 ± 113.3 pg/mg vs. 16.0 ± 4.7, p b 0.05) in the serum of
MCT-treated rats. EA (30mg/kg/day) treatment reversed these changes
(p b 0.05) (Fig. 5A-G). For TNF-α, there was no statistical signiﬁcance,
despite a downward trend after EA treatment (Fig. 5H).
3.5. EA inhibits inﬂammasome activation in rats with MCT-induced PAH
Western blot analysis demonstrated that the lung NLRP3 (Fig. 6A, B)
and caspase-1 (we analyzed the active subunit p20) (Fig. 6C, D) were
up-regulated in MCT-treated rats compared with the control group.
Activated caspase-1 (p20) contributes to the maturation of IL-1β [8,9].
Consistentwith the increased ratio of active caspase-1(p20)/β-actin, in-
creased expression of IL-1β (the active subunit p17) was also observed
in the lungs of MCT-treated rats (Fig. 6E, F). These results suggest a role
of NLRP3 inﬂammasome activation in lung inﬂammation under the
pathologic condition of PAH in rats. In MCT-exposed rats treated with
EA (30 mg/kg/day), we found an attenuation of lung NLRP3, caspase-1
(p20), and IL-1β (p17) expressions (Fig. 6).
4. Discussion
The major ﬁndings of this study were as follows: 1) EA improved he-
modynamics (dose-dependent), right ventricular hypertrophy and pul-
monary vascular remodeling in rats with MCT-induced PAH. 2) MCT
up-regulated oxidative stress, NLRP3 signal pathway and increased
inﬂammatory activity in the lungs and serum. 3) Pathophysiology im-
provements with EA treatment were associated with a downregulation
of NLRP3 signal pathway.
Progressive increases in pulmonary vascular resistance and pressure
impair the performance of the right ventricle, resulting in right-heart
failure, and ultimately death [17]. The RVSP, which well reﬂected the
pulmonary artery pressure, decreased after EA treatment. The right ven-
tricular response to increased pressure load is recognized as critical to
survival [26]. MCT-treated rats developed right heart failure with in-
creased RV/(LV + S) ratio and medial hypertrophy relative to the con-
trol group. EA prevented MCT-induced PAH and subsequent right
heart failure. BNP is an ideal biomarker reﬂecting RV dysfunction and
disease severity in PAH. It has been considered a prognostic parameter
in PAH treatment guidelines [25]. The BNP level increased in MCT-
treated rats, indicating infarcted right ventricle dysfunction due to
PAH. EA improved impaired right ventricle dysfunction and reduced
BNP levels.
Although, several studies have demonstrated the potential beneﬁts
of natural antioxidants in PAH, the underlying mechanism has not
been fully determined. Genistein and resveratrol have been demon-
strated to prevent MCT-induced PAH in rats [7,27]. In present study,
we identiﬁed EA as another potential treatment for PAH, and found
the common mechanism of action for antioxidants in PAH.
Inﬂammation plays a key role in human PAH as well as in experi-
mental models [28,29]. In response to injury and stress, lung vascular
cells produce inﬂammatorymediators, thereby recruiting inﬂammatory
cells. Inﬂammatory cells might perpetuate the release of cytokines and
growth factors, forming positive feedback loops. These processes could
lead to vascular remodeling by matrix remodeling, collagen deposition,
and vascular cell proliferation andmigration in PAH [28,29] and, ﬁnally,
to increased pulmonary resistance and right heart failure.
IL-1β is a prototypic multifunctional cytokine involved in inﬂamma-
tion. Many studies have indicated that IL-1β plays a pivotal role in the
pathogenesis of PAH [2–7]. Consistent with previous ﬁndings, we
found that serum and lung IL-1β levels are elevated in MCT-treated
rats, along with the up-regulation of other pro-inﬂammatory cytokines
(Fig. 5). Additionally, EA can attenuate MCT-induced PAH while
inhibiting inﬂammation in rats. These results further demonstrate the
Fig. 6. EA inhibits lung NALP3 inﬂammasome activation inMCT-treated rats. RepresentativeWestern blot results and graph showed lung NALP3, caspase-1 and IL-1β expression 4 weeks
after MCT injection in different groups of rats. Relative protein levels of NALP3, caspase-1(p20) and IL-1β(p17) were determined after normalization with β-actin. Data are the means ±
SD. The NLRP3 inﬂammasome pathway was activated in MCT-induced PAH rats, further EA treatment can down-regulate this signal pathway. *p b 0.05 versus Control group; ▲p b 0.05
versus MCT group; #p b 0.05 versus Control group. n = 6 per group. EA, ellagic acid; MCT, monocrotaline; IL-1β, interleukin-1beta.
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PAH.
In addition to the previouslymentioned inﬂammatory reaction, OS is
another characteristic of PAH.OS reﬂects an imbalance between the sys-
temic manifestation of ROS and the antioxidant ability to eliminate
these reactive intermediates. A major role for the increased generation
of ROS in the pathogenesis of experimental PAH is indicated by antiox-
idant intervention studies performed in fetal lambs [30], hypoxia-
exposed mice [15] and rats [31], permanent high-ﬂow exposed rats
[32], and monocrotaline-exposed rats [14]. Additionally, PAH patients
present increased OS [33]. SOD acts as the ﬁrst line of defense against
ROS by dismutating superoxide to H2O2. Kamezaki et al. reported that
gene transfer of extracellular SOD ameliorates MCT-induced PAH in
rats [14]. ROS-reducing strategies induced by an SOD mimetic improve
chronic hypoxia-induced PAH [15]. In the present study,we detected in-
creased OS in the lungs of rats in MCT group. EA-treated rats presentedimproved vascular remodeling coupled with decreased OS. However,
the exactmechanismbywhich antioxidants prevented PAHand inﬂam-
matory status remained elusive until the discovery of the NLRP3
inﬂammasome.
TheNLRP3 inﬂammasome is activated in several types of lung injury.
Wu et al. suggested that the alveolarmacrophageNLRP3 inﬂammasome
may sense lung alveolar stretching to induce the release of IL-1β [11].
NLRP3-deﬁcient mice display a suppressed inﬂammatory response
and blunted lung epithelial cell apoptosis in response to hyperoxia-
induced acute lung injury [34]. The generation of ROS is central to
NLRP3 activation [8,12], which in turn, is critical to the activation of
caspase-1 and IL-1β [8,9]. The roles of inﬂammation, caspase-1, and
IL-1β in thepathogenesis of experimental PAHhave been shownby sev-
eral speciﬁc antagonist intervention studies performed in rats with
MCT-induced PAH respectively [2,35,36]. Our ﬁndings are in accordance
with previous studies implying that polyphenolic antioxidants can
140 B. Tang et al. / International Journal of Cardiology 180 (2015) 134–141attenuate MCT-induced pulmonary hypertension in rats [7,27]. Since
Villegas et al. reported that the NLRP3 inﬂammasome pathway was
activated in hypoxic PAH in mice [15], this result contradicted the
ﬁnding that IL-1ra cannot inhibit the development of PAH in chron-
ically hypoxic rats but can in MCT-treated rats [2]. Those two re-
searches suggested the pivotal role of IL-1β in MCT-induced PAH
but chronic hypoxic PAH. Here, we showed that the MCT can induce
increased OS, IL-1β elevation and NLRP3 inﬂammasome activation in
the lungs. Considering the respective roles of OS, ROS, inﬂammation
and IL-β in the pathogenesis of PAH, as well as the interactions be-
tween ROS, the inﬂammasome and IL-1β, we propose that the effect
of antioxidants on PAHmay contribute to the inhibition of the NLRP3
inﬂammasome by inhibiting OS.
EA inhibited the NLRP3 inﬂammasome in MCT-treated rats, primar-
ily by exerting its antioxidant effects to reduce OS, which has been dem-
onstrated in other studies. In ischemia–reperfusion (I/R) injury, EA can
ameliorate lung injury and OS after intestinal I/R injury in rats [37]. In
lung disease, increased ROS production activates inﬂammatory cells in
the pulmonary defense system, causing pulmonary ﬁbrosis in the
bleomycin (BLM)-induced lung ﬁbrosis model [38]. EA attenuates
BLM-induced pulmonary toxicity in rats [39]. Pulmonary hypertension,
and exercise capacity reduction are also present in BLM-treated rats.
These ﬁndings aided our understanding of that EA treatment provides
beneﬁts in MCT-treated PAH rats.
Limitations of our study include the absence of speciﬁc NLRP3 antag-
onist interference or NLRP3 gene deﬁciency animal analysis to conﬁrm
the role of NLRP3 in PAH, additional experiments if EA can reverse the
established PAH.
5. Conclusion
The pathophysiological changes in inﬂammation-related PAH
may involve the activation of the NLRP3 inﬂammasome pathway.
EA can attenuate MCT-induced PAH, pulmonary vascular remodel-
ing and right ventricular hypertrophy through exerting inhibiting
NLRP3 inﬂammasome signal pathway. It was demonstrated that
EA was a promising treatment candidate for PAH and established
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